SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination is 53.9 percent compared to 37.2 percent in a checkpoint inhibitor... | May 26, 2022

Related Keywords

United States ,China ,Canada ,Angelos Stergiou ,Michaela Fawcett ,Jeffreys Weber ,Allison Soss ,Raquel Cona ,Langone Health ,Company Wilms ,Genfleet Therapeutics Shanghai Inc ,Nasdaq ,Merck Co Inc ,Strategic Communications ,Life Sciences Group Inc ,York University ,Melanoma Research Program Center ,Perlmutter Cancer Center ,Memorial Sloan Kettering Cancer Center ,Globenewswire Inc ,Response Rate ,Control Rate ,Progression Free Survival ,Overall Survival ,Sciences Group ,Clinical Trial Collaboration ,Supply Agreement ,Top Line Clinical ,Deputy Director ,Cancer Center ,Sloan Kettering Cancer Center ,Fleet Therapeutics ,Annual Report ,Sellas Life Sciences Group ,Nc Stock Exchange ,News ,Information ,Press Release ,Verall ,Response ,Gate ,F ,Ercent ,Us ,Similar ,O ,Checkpoint ,Inhibitors ,Alone ,Disease ,Control ,Or ,Ups ,Combination ,Ompared ,N ,Heckpoint Sls Us81642t2096 ,